Dendritic cells (DCs) are currently the most potent antigen-presenting cells, playing a crucial role in the body's immune processes. By presenting specific antigens to T cells, DCs can induce the massive proliferation of antigen-specific T cells, thereby eliminating pathogens (such as tumor cells or viruses) bearing specific antigenic markers to achieve therapeutic effects. Traditional methods of inducing DCs from mononuclear cells are considered insufficient for achieving sufficient DC numbers. Approximately 10^7 DCs can be obtained from 100 mL of peripheral blood, a quantity far below what is required for DCs to exert clinical therapeutic effects. This DC shortage severely hampers the advancement of DC-based clinical research and applications. This kit enables the in vitro generation of sufficient quantities of DCs, yielding over 100 times more DCs than traditional methods. It features simple operation requiring no cell sorting, allowing direct culture initiation from mononuclear cells; serum-free culture ensures greater safety for clinical research applications; and it generates mature, terminally differentiated DCs with potent antigen-presenting capabilities.